Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CRC 1470, Z01 and B02)
Deutsche Forschungsgemeinschaft (CRC 1470, Z01 and B02)
NextGenerationEU (PNRR M4C2-Investimento 1.4 – CN0000000041 – PNRR_CN3RNA_SPOKE 9 and PNRR P20225EMBT)
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Accepted: 7 May 2025
First Online: 23 May 2025
Declarations
:
: DC and AA are founders of “NanoPhoria”, a pre-clinical stage biotech company and National Research Council spin-off that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles (www.nanophoria.com). FPL declares no competing interests.
